Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.44 |
| ▸ | AGXT | P21549 | 1/20 | 0.37 |
| ▸ | ATP4A | P20648 | 2/20 | 0.32 |
| ▸ | ATP4B | P51164 | 2/20 | 0.32 |
| ▸ | ATP1A1 | P05023 | 1/20 | 0.32 |
| ▸ | ATP1B1 | P05026 | 1/20 | 0.32 |
| ▸ | ATP1A3 | P13637 | 1/20 | 0.32 |
| ▸ | ATP1B2 | P14415 | 1/20 | 0.32 |
| ▸ | ATP1A2 | P50993 | 1/20 | 0.32 |
| ▸ | ATP1B3 | P54709 | 1/20 | 0.32 |
| ▸ | FXYD2 | P54710 | 1/20 | 0.32 |
| ▸ | ATP1A4 | Q13733 | 1/20 | 0.32 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23988475 | 0.80 | AGXT (0.57) | SARM1AGXTATP4AATP4BATP1A1 | |
| SCHEMBL28643701 | 0.79 | SARM1 (0.47) | SARM1AGXTATP4AATP4BATP1A1 | |
| Hydrochloric Acid SCHEMBL8977353 | 0.78 | SARM1 (0.46) | SARM1AGXTATP4AATP4BATP1A1 | |
| SCHEMBL6440042 | 0.74 | SARM1 (0.61) | SARM1ATP4AATP4BATP1A1ATP1B1 | |
| SCHEMBL21945694 | 0.74 | SARM1 (0.61) | SARM1ATP4AATP4BATP1A1ATP1B1 | |
| SCHEMBL23988439 | 0.74 | SARM1 (0.61) | SARM1ATP4AATP4BATP1A1ATP1B1 | |
| SCHEMBL23988452 | 0.71 | SARM1 (0.46) | SARM1ATP4AATP4BATP1A1ATP1B1 | |
| SCHEMBL23988397 | 0.71 | SARM1 (0.46) | SARM1ATP4AATP4BATP1A1ATP1B1 | |
| SCHEMBL23988381 | 0.71 | SARM1 (0.46) | SARM1ATP4AATP4BATP1A1ATP1B1 | |
| SCHEMBL9835758 | 0.68 | AGXT (0.42) | SARM1AGXTATP4AATP4BAGBL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210338650-A1 | CXCL10 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338650-A1 | CXCL10 Inhibitors | CXCL10, CCL5, CCL11 | SARM1 3076/4885AGXT 900/4885ATP4A 4581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.